Please provide your email address to receive an email when new articles are posted on . Patients with autoimmune or connective tissue disease often experience permanent scarring and skin changes.
Even in advance of the results of an ongoing phase 3 trial in patients with cutaneous lupus erythematosus (CLE), anifrolumab — a monoclonal antibody targeting interferon — might not be best reserved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results